| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Chronic morohine administration induced mRNA expression of serine racemase in all brain regions and spinal cord and that of D-amino acid oxidase in forebrain of rats. Dynorphin A and its derived peptides interact with opioid and glutamate receptors at their N- and C-terminals, respectively. Pretreatment with peptidase inhibitors augmented Dyn A (1-17) or (1-13)-induced antinociception by approximately 50- or 30-fold with no sign of allodynia when administered intrathecally at low doses. Pretreatment with peptidase inhibitors induced neuropathy. These findings showed that intrathecal administration of low-dose Dyn A (1-17) or Dyn A (1-13) increased antinociception under pretreatment with ACP, but without signs of allodynia in rat. These results indicated that administration of chronic morphine increased dynorphin A (1-17), and then induced nociception through NMDA receptors.
|
